JavaScript DisabledOur website uses JavaScript. Please confirm that JavaScript is enabled in your browser.
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical AssociationDemonstrating the Utility of Blood Biomarkers in Predicting Amyloid Beta Accumulation in the Brain
Updated:Publications
The mass spectrometer LAMS-50K, which Shimadzu Corporation released in 1988, has been recognized as an IEEE Milestone.
Visit Shimadzu at AAIC 2023 - Alzheimer's Association International Conference
To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
Visit Shimadzu at AAIC 2022 - Alzheimer's Association International Conference
Column:MALDI-MS for Glycan Analysis
The MALDImini-1 Honored with iF DESIGN AWARD 2021
Updated:Publications (Technical article for MALDImini-1)
The MALDImini-1 Bestowed the Honor of the “Best of the Best Award” by Red Dot for Product Design
Statistical Analysis of MALDI Mass Spectra Supporting the Discovery of a Novel Species of Genus Pseudomonas
Does the Plasma Amyloid-β Composite Biomarker Associate with Cognitive Decline in Preclinical Alzheimer's Disease? IP-MS will answer.
Discovery of a Novel Class of Hybrid Lipopeptide Compounds using the HiRID™-MS/MS Technology in Collaboration with the University of Tokyo
